“…27 Furthermore, more than 97% of the anti-idiotype antibody response to adalimumab, golimumab, and certolizumab, all 3 of which are either human or humanized anti-TNF antibodies, could be inhibited by TNF. 25 All-in-all, the vast majority of antibodies formed to these TNF blockers appear to be neutralizing, anti-idiotype antibodies. Strikingly, >90% of the antibody response to the chimeric infliximab could be inhibited by TNF.…”